CHMA - Earnings call transcript Q2 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thank you for standing by. This is the conference operator. Welcome to the Chiasma's second quarter 2020 earnings conference call.

As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. Instructions]. [Operator like conference now Garmont, to turn Relations. Investor to would over the Glenn I ahead. go Please

Glenn Garmont

a operator. you issued operating press be quarter we our website. our our XXXX which release, found results on financial Thank and to second Welcome conference of may copy call. Today,

expectations to the potential agreement and this will market of are or the commercial octreotide and plans and our from and potential based the additional and adoption, certain of for from manufacturing the supply, financial marketing the our the and success our convert statements of lanreotide These expectations MYCAPSSA the product hiring, MYCAPSSA, commercialization potential ability be During to number including a and MYCAPSSA current injections, EU of our launch manufacturing forward-looking Royalty the and commercial us. approval. their of the employees regarding its the therapeutic expectations plans our potential timing United we topline and to timing events and the and submit on of and that trial royalty market customer-facing results to under our MPOWERED with about our MYCAPSSA FDA funds regarding concerning timing receipt call, available the statements and information States, Partners endocrinologists HealthCare but the including results concerning application we expectations MYCAPSSA, and patients of in of of regarding availability U.S. reimbursement to circumstances, anticipated MYCAPSSA not and additional making plans composition acceptance of statements size limited expectations for submitted to MYCAPSSA, an supplement for market supplement for

or those in our ended You carry filed results Factors our should the uncertainties, meet including section due of risks out or goals, the achieve filings as June Except We quarter XX-Q any read as on statements, not detailed in future events SEC. our expectations. SEC law, subsequent these place XX, intentions Actual or may to information statements. for We numerous events as a our by differ and update Form or not plans result these may well forward-looking materially to reliance required contained the undue disclaims Risk XXXX, Chiasma as with the whether of new these obligation encourage everyone documents. to otherwise. with information,

the Medical of Executive and Bill Chief Joining President today Affairs Varadan, and and Officer. Officer, Officer, call Executive Mark Clinical Chief Commercial Development Fitzpatrick, and President Kannan, Vice Senior is Vice Financial President Raj Anand Ludlam, Principal

Raj the I Now to Raj? Chief would to like Executive Chiasma's Officer, Kannan. over turn call

Raj Kannan

Thanks Glenn. joining And thank today. for the call you everyone

during second parallel to U.S. in have second which Phase to our of quarter, relate of in We review areas MPOWERED Union. of approval MYCAPSSA my been advance the productive while for both in of launch support the quarter, MYCAPSSA MYCAPSSA. the to three the commercial highlight in trial X I all wanted to the very potential preparing European continuing the

broad the received. indication approval we is first The and the FDA

resources the The preparedness. second commercial support is planned launch third is our our the And robust launch. to

patient in in believe significant injectables. acromegaly. with of the therapeutic become is treatment challenges transforming a a population a with advancement could somatostatin First, key was company. XX the and goal the care truly Chiasma believe June a FDA We MYCAPSSA, a only first a the somatostatin achievement transformational company delivered new stage pharmacological existing on analog faces oral of into We approval and the marking significant comeback that we what analog significant commercial on XXXX vital standard in of for MYCAPSSA

reduce potentially develop the validates technology burden platform allows designed to delivery the approval that with injection us oral TPE, we or believe chronic our rare Transient this of for to people Additionally, therapies Permeability diseases. Enhancer additional

to estimate label promote long lanreotide. the allows all we us approved opportunity the with either us responded patients octreotide who the to access MYCAPSSA Importantly, or provide label term broad We injectable maintenance to of benefit. XX% tolerated X,XXX the be and believe MYCAPSSA surgery treatment market which treatment other approximately for approximately the therapy not to somatostatin we to provide do options pituitary analog the U.S. in sufficient estimate including remove to whom patient clinical with tumor

Now my with let on product to a highlight. indication, we have broad as our launch an second that approved comment we topic preparedness

with fewer targeted estimated this that than on ourselves acromegaly are on indicated our market accounts. force. by approval X,XXX of approximately we is oral managed small to the June very acromegaly innovative sales XX and XX% patients medical specialty U.S. us call, market As a therapy allowing is concentrated, It with

today, initial first review are the gaining market Anand an face-to-face be in acceptance customer-facing team, As quickly nimble hired a to of adapt provide which the to appropriate our increases to leverages interaction conditions, frequency our this on activity this or XX which to We of and endocrinologists. about of readiness allows initial will capability expand when team, telehealth returns including full moment. including levels intend across one-half the physicians more individuals. by is for our of of wave normal. remote have depending of up approximately force In COVID-XX, a U.S., and commercial that this detailed we of concentrated us force launch to planned age if

of with to product our of release supplies to work supply commercial readiness, our packaging continue terms we MYCAPSSA. manufacturer In finished initial the commercial

this to primary FDA's quarter. commercial CBE-XX end the activate octreotide supplement FDA NDA be to And our our to a XX, now to June referencing we our manufacturer. We to and API submitted by we available manufacturing the this the approved completed expect pharmacies On work be product await made of specialty acceptance.

produced finished subject to and sufficient today release, have our MYCAPSSA demand. of As commercial projected capsules meet we to initial packaging

response which and following relevant in safety with and XX-week we treated over the As we efficacy walk label MYCAPSSA July, generated with longer meaningful term. through this were with you OPTIMAL very of XX-week clinical MYCAPSSA announce details additional the trial, open data in late in pleased durability Bill will the data extension moment. on on a CHIASMA patient the demonstrated

the we are well planned HealthCare excluding the net with approximately the last marketable equity of ended financing and believe quarter $XX.X equivalents, and Partners million in million We commercial and cash, completed $XX MYCAPSSA $XX.X launch financing in revenue cash, proceeds our we interest second activities. cash received that another restricted through from development we securities agreement million month capitalized mid-July. Royalty we support with to Lastly, ongoing

an of in have Partners to-date of the And under the the from million this year quarter. achieved U.S. and will In our remain $XX Bill? fourth summary, MYCAPSSA every Royalty I the now milestone turn we for the MYCAPSSA Following Ludlam, of call we first sale the we commercial planned HealthCare launch agreement. over supply of terms the Bill exciting availability in track commercial and to to commercial receive on expect additional

Bill Ludlam

which the Raj. XX-week and completed we XX open OLE with an trial. XX-week that On with OLE normal label the XX-week, the as CHIASMA MYCAPSSA notably generated end who during OPTIMAL of responders treated condition, phase oral MPOWERED CHIASMA patients the enrolled recently for preference on label OPTIMAL at All normal like response the we end the in or from for normal meaning open OLE into XX% patients extension review update the patients to MYCAPSSA were completed released this and of at for data MYCAPSSA XX-week manage Recall maintained data all XX% provide OLE within the the was recently OLE the period. the their within XX Thanks enrolled to within who today's CHIASMA DPC of call, placebo additional I on maintained OLE OPTIMAL the IGF-X continued controlled results of the our the of an patients and the limits, study their therapy limits will period. learned period additional with XX extension to you completed into the treated completed continue double-blind the would limits the or MYCAPSSA XX-week of of trial population the to mean MYCAPSSA, enrolled that OLE study levels and XX-week clinical IGF-X XX I announced, who insights in reflecting the strong provide their DPC for the XX-week XX% period. OLE trial

we during was consistent the trial believe the with of In profile term OLE duration safety seen label noted with in noted generally safety exposure. efficacy and demonstrated observed increased the MYCAPSSA durability CHIASMA summary, safety extension XX-week longer data pivotal the open the trial. the with patterns the in of no the of Finally, OPTIMAL the from new

potential to turn the to a trial in high X support will designed of over approval it Importantly, our MYCAPSSA Phase now I inherent confirmed the longer of regulatory level ongoing to also the drug clinical term. regime MPOWERED the EU. patients

patients a have the XX nine-month of phase protocol, MYCAPSSA the total randomized per responders trial the XX nine-month, to as As four in of the phase. randomized and double-blind, remain of completed today, into active patients trial placebo-controlled

EMA's trial the the in top-line controlled work data has to met ongoing of clinical we positive, is The in EMA fourth the randomized half continue to plan for trial of site continue trial. complete the of sites progressing of COVID-XX marketing We next the nine-month trial year. with and the Notably, report is planned first important to as the the safety our we required trial authorization the to randomized the If to and personnel expect ensure light already pandemic. to in submission the this application of patients the XX phase minimum quarter to XXXX. patient from of

physicians complete, MPOWERED XXX This when lanreotide. globally call to of been point, than across our the Anand should from turn on prescribing provide switching commercial Phase Anand? considering an have clinical activities. over patients set Importantly, data our studies. octreotide in are three to confidence X I or their evaluated all At will update the MYCAPSSA patients extensive will is for who acromegaly this more trial

Anand Varadan

Bill. Thanks

commercial advance As continuing launch expect Raj the commence MYCAPSSA, we in indicated, to will of the quarter. which we are toward fourth

main have reimbursement people now we for to preparations are focused to market other the Our the and board and launch, promotional access conditions changing MYCAPSSA. patients support three to patient pivot execution launch on on support that execute transitioning provide and the can market priorities,

in with rare talent experienced competitive market commercial the front, our successful disease and with have their to settings credit. On people numerous product top we launches internal built highly team

sales patient services have support currently about are customers hired wave trained and services also first they and our educating MYCAPSSA and We and now our personnel of are.

access Access provide support advance management account patients. our and the to team Support to to access, ready personalized patients transition payors to CAPS assist or and for engaging broad injectable. arrange home is MYCAPSSA team Patient and And process obtain with Chiasma delivery of providers from to is Our process obtaining the key

We are experience. of team extremely passion team having pleased with drive, several prior acromegaly sales of selling to been track success to Chiasma record the and attract of we and members the quality, able with our

and therapy. much-needed oral a provide painful to Our and the injection site having a by builds LAR workdays physician's our first the octreotide execution will alleviate injectable awareness we to promotional injections many somatostatin to site only therapy. current with the injection This or pain, monthly analog, visit had their acromegaly lanreotide office on endured treatment includes to current help patients on burdens treatment efforts a patients of As raise face from for have option challenges believe reactions MYCAPSSA missed

of we benefits program have into after approval in of and patient Our and about MYCAPSSA. both multifaceted promotional HCP the more digital signs potential effect went seen interest encouraging immediately learning FDA

engage of been wave are end top-tier to currently to who team promotion endocrinology interactions restrictions. not customers equipped to with the at This representatives has personal first face-to-face remote Our of July. to tools began due COVID-XX sales open accounts

and injection with our team. MYCAPSSA for current in to with and customer-facing to X,XXX customer-facing It total size than will that sized current accounts, important ultimately permit. be that we worth a expect broad fewer number treatment. a up analog as be payors, plan XX% by with XX seen least at the about of to anticipate benefits concentrated effective patients is can provide coverage, payors innovation efficiently somatostatin is account we half have to members one already treated scale believe With they as approximately noting conditions we significant expect As reminder, customer of we base par their budget. market we With an on that medical treatment the team will ultimately we with patients

can to with injectable for new to from payors clinician, So telehealth to to to over are MYCAPSSA existing patients expected can the coverage therapy changes a and we a the of available treatment contact, is Overall, in coming represent an administration to soon not a and therapies evolve now learning. to based very patients, a or the be to MYCAPSSA our our confident the over new well us Mark. believe succeed entire are competitively is marketplace process announced are opportunity home. strategy launch newly oral believe to oral well-positioned product our patient Internet, to go-to-market bring accomplished acromegaly through phone own or efforts our is to we policies with are MYCAPSSA entirely limited prescribed and positions MYCAPSSA if them. bring are we MYCAPSSA and MYCAPSSA phlebotomy to cost to physical adapted a desired, converting in to from month. at we need broad continue prescription injectable and And lab ready current in consultation We plan communicated environment ensure the commercial the COVID-XX implemented by and on of that mobile working patient MYCAPSSA pricing delivery Notably as option. We access obtain with as to excited the of

Mark Fitzpatrick

Thanks Anand.

the by position are and activity. commercial call, recent for at was launch our cash As our at more XX capitalized of summarized strong June Raj believe planned outset the the we financing given well we

$X.X continuing administrative compared stockholder this the are of the the in were the U.S. costs. current the ended were XXXX. compared were months the by the planned capsules of we XX, second the disease As fourth XX, Research year. period by same $X.X with XX, $X.X publications with development other million period for expenses the compared June General commercialization $XX ended for our clinical ended for prudently period Research XXXX further results and $XX.X our compensation-related offset current and for with year XXXX were same million and will expenses quarter prepare ended resources and the XX, million with which driven planned six MYCAPSSA in for we for a XXXX our compared million million the trial the to of six which $X.X to million precommercial regulatory launch, results scientific state period period that associated ensure to for of three manager increase $XX.X million primarily an of of the General in were quarter months increased for second continue have expenses XXXX, cash quarter literature were include the June year expenses June The as increased octreotide XXXX. for XXXX. The emphasized for activities costs costs, expenses of decrease value. and to XXXX. million increase months support manufacturing in in respectively, $X.X were million registry, development commercial June XX, with and in we million past, the $XX.X XXXX costs business we six June investing in and and administrative $X.X ended administrative same same

to Going for forward, manufacturing to longer costs in expense production but will the commercial will captured MYCAPSSA of related no be R&D be inventory. capitalized supplies

million $X,X $X.XX For of with XX, period compared June loss the a net basic share per loss was same per ended or XXXX, $XX.X or the million basic of for share quarter net XXXX. $X.XX

or period $XX.X share months $X.XX share per For XXXX. the net with XXXX, compared per was June million basic or basic the $XX.X for of a of ended net same six loss loss XX, million $X.XX

estimated premature at provide commercial to for XXXX guidance availability, product and our variables time. it many the XXXX the be plans associated timing financial would of Given this and with

information helpful. However may the following be

half pre-PDUFA our expenses the Our of half approximately of expenses March These of and commercial the as in support ended precommercial please employees at significant included that API MYCAPSSA XX and in operating employee the to to were increasing planned and launch expenses costs hire were XX the of bringing the XXXX manufacturing team. in this are entirely Also expanding headcount gradually mind our team July, we our July. to bear customer-facing planned our total readying year and first of half produce end are first of contained program going to completed with full-time R&D in MYCAPSSA's capitalized in These promotional be Immediately XXXX will $XX expect customer-facing began costs now that well approval, increase. inventory expenditures million. will We cost following as ongoing expense. incurring forward. we we

for if addition, have first XXXX. anticipate the In half submission spending we in trial we MPOWERED positive results, increased of EMA

are potential pipeline the likely until cost low into launch to development, further Finally, product U.S. for progress relatively of additional which MYCAPSSA. we we expect be

less the Partners $XX of MYCAPSSA. approval an next FDA course, received million commercial and cash, technology. more year seek pipeline is additional detailed from anticipated X and top-line equivalents, interest first under trial will, revenue XXXX. of guidance. We we approximately revenue refine our to continue expected commercial capital quarter, if $XX plan, to ended we adequate our the agreement. for and we utilizing our certain submission fourth the launch in $XX.X growth TPE regulatory In July, estimates also $XX.X the with the with advancement restricted mid-July Phase in by transaction after We April financing marketable U.S. announced We Royalty of In including commercial second compared quarter, December equity from EMA million million company from received a as planned million as triggered offering. previously of will XXXX, an fourth net million evolve expected our quarter milestones, MYCAPSSA positive cash we the of HCR completion expenses underwritten developmental and from trial also raised securities payment of U.S. achieve provide data HealthCare MPOWERED of XX, in in have in the which cost $XX.X cash, believe July, we these half activities MPOWERED to the planned of Upon proceeds our the financing the

over before let Q&A. to we Raj call Now turn things me back the to open

Raj Kannan

Thanks Mark.

planned We acromegaly people new potentially treatment of are transform in of excited of need to the commercial with for option. oral U.S. a launch MYCAPSSA life the

Q&? a for look our assembled plan. commercial we you the world-class executing team have robust on open the and forward Operator, would We please to lines

Operator

Instructions]. [Operator

Piper Our first with Edward open. question line Tenthoff is from is your Mr. Sandler. Tenthoff,

Edward Tenthoff

on anything hear given there very success. the Okay. are was the so And you characterization for respect in of all to for that Guys, for I manufacturing Whether bit you on in supply all? launch? little Really supplemental? you that you to quarter. to Thanks then Thank a much. what more to little exciting bit a fourth sense was pay hand the a manufacturing in much. the congrats at supply, with does more us have impact And what can set launch get attention there? to give terms wanted supplemental the

Raj Kannan

the Ted. will I well. will Hi overarching an comment the make to comments as question. Thanks supply to additional Raj. on then supplement, provide Mark This the it and I manufacturing for is any add

when On the is uncertainty approval. guidance review, a that approve are the and filed the actual than But there approve before, then accept had we XQ current terms in accepts a expected as it we earlier we there FDA possibility or the launch. possibility a our which decision time, supplement given had of are of accept around maintaining will of approves We FDA and the it, an to stated mentioned it was on manufacturing waiting the it. FDA the if we manufacturing supplement, CBE-XX filing

projected commercial meet indicated our supply that have initial terms In hand we in prepared we demand. of remarks our had in to adequate supply,

us then that our in. acceptance supply allows weigh put marketplace. However, upon something to in incumbent that I free feel FDA the CBE-XX of that commercial have if missed please to into comment, the is which Mark,

Mark Fitzpatrick

captured think Raj, I fine. just have you it

Operator

Brandon Cantor ahead. from Fitzgerald. with Folkes go The Please question is

Brandon Folkes

quarter. questions during for my the Thanks the all taking congratulations Hi. and on progress

important out the following with since on an be would need a your the approval And in quickly the prior channel? supplement post Just discussions maybe and able you terms into How to of weeks? on launch, Would question. few the getting based approval, then just inventory from secondly, maybe of place approval to do prescribers on since has is that adoption become bit of more see that little a year? bit there in wanting think you place, MPOWERED in prescribers that drive the or Thank emphasis that a you. may may to more aspect the prescribers any further U.S.

Raj Kannan

Brandon. Hi questions. those Thanks for

believe to have pharmacies would foremost, our and the supply the of prepared TPL I by get to we able specialty our on availability, commercial be or First said we quarter. remarks, that supply the end this in

acceptance is the the we that still think depends supply of into we commercial release can I CBE-XX Whether the that said our as expectation. So before marketplace on manufacturing supplement. FDA's

of sort question. that answers the So first

question was OPTIMAL. Obviously, we data to important complementary MPOWERED. trial The second is as MPOWERED will know that on an generate

information to the that and we answers so on injection a which are that that able the mitigation does Brandon. aspects the that the a mitigation expect monthly would is your would daily a to that Hope contribute there of patients be quality whether symptom And trial. both generate data non-inferiority we we for hypothesis address physicians attention benefit to that symptom life will dose versus with many importantly, MYCAPSSA the able versus because kind injectables. of injectables, be to And relative questionnaires head-to-head is depot pay of one, questions,

Brandon Folkes

It you very does. Thank much.

Operator

line is open. The H.C. next with Mr. question is Wainwright. your Tsao, Douglas from Tsao

Douglas Tsao

Thanks afternoon. for question. Good the Hi. taking

Just following from maybe Brandon's up of little a question. bit on

terms curious you post-approval. of interacting have in days been that Just the with physicians early

excited about, or be you. Just of helpful. most on potentially feedback in they in Just switching? they from patients are types there have they are color the any of interested getting of MYCAPSSA points are terms what are clinicians been what Thank most you point would

Raj Kannan

I this and from option let quite and response for we specific Thanks have will with introduction that well in say in to Anand from of and KOLs that the our a patients. gathered very I that important And that them put ground. has our weigh approval especially force COVID-XX will encouraging, more Anand? an is environment, since in the overarching our particular both MYCAPSSA payors. our Doug. HCPs, on as Hi on have physicians insights the primary research question. consider as the field to for we engaging been the been patients

Anand Varadan

Hi I Sure. Thanks appreciate Doug. it. Raj.

sales Doug, been field just So our of organization the now there out end since July.

whom are it of eligible we that product of interactions seen for couple therapy are been viable reception the across I on it who respect, much lanreotide is, market weeks. our patients be it been overall for with an it. expectations MYCAPSSA has be And I level for it's profile quite and tracked of is an prior that coming be received how The So since oral would a have what the would the a oral who think then, for around pretty for with profile and in as or those essentially have on And of in what strong. research. patients eligible that then option pleased that specific and think would therapy that octreotide the we

level website well and the the this with HCP basing seem our engagement patient traffic on the have had visitors that both am have encouraged out as as our in we the The various organization that of of that field. is sales And we the have thing that interest other and HCPs saw before the the part by patients was aspects we been it. I on to

modules. are doing a are various been. gather They not have that they time. the downloading So They through from normally we what and leaving. spending are going coming just agencies, exceeds are are what they information. from in benchmarks this the rate at our They And

says optimistic all and eligible in think for. product the So us and clinicians they are through mood that coming we together that for one is that puts put the the an of also think to patients that

Douglas Tsao

Great. And Europe terms controlling the of one has quick greater much virus. success follow-up MPOWERED. in of had in terms then just Okay. Obviously

anticipated, that at those really is any that not the Or needed you. sort So That go the just be put study had not the have of not to you would we to those in effect are modifications point, as situation significant through really this helpful of place, some Thank the understand report. or just plan? there? given executing as

Raj Kannan

Yes.

So let things a prepared of from right. me provide just Bill's remarks, couple

remarks already Bill his folks that the had randomization had then XX was XX and EMA completed. So requirement, that in as the prepared remind to minimum have the responders And requirement here patients mentioned I of we XX for randomized patients. them want

we are we So patients this And above that global well have and a particular is mark active. trial. four

the that So we is just else it' add to there would Europe anything but not like are on have to you that track. alone, Bill, provide confidence track? MPOWERED on we that is

Bill Ludlam

No.

So as using are along, a data. for accounts have analysis, we average saying missing we all which been any weighted time

four are moving as exactly I plan. just only have We patients, Raj along very and nicely is mentioned mentioned Everything to RCT. earlier, that still the in

Douglas Tsao

ago? been the in just virus. just maybe get months But given you were potentially I of weighted factor asking, the less anticipated ex-U.S. several any just quickly terms was of, I accounted know data. that control clarify, people time obviously for average to a just missing that of able to And how Has

Bill Ludlam

haven't the began were able the close provide working patients, the working drug and with with sites are of loss kinds closely create ongoing there into We patients I patients. that up you to trial. specifics been very the safety very proactively measures due is process closely that any This tell an can not got that we again. early COVID-XX to Well, issues. to all on follow to the we in has very,

four been as that we have this as only planned that currently well. able to And said, through we remaining. and we navigate really patients go through So very are to continuing

Douglas Tsao

offline. Okay. I with will follow you

Bill Ludlam

the report on particular we and about that the top-line remain remain to quarter also in as excited track We still well. milestone fourth

Raj Kannan

Absolutely.

Douglas Tsao

Great. Okay.

Operator

The is Brookline Mr. next Raja with Raja, line Capital from is Kumar open. Market. question your

Kumar Raja

the for my supplement, will and whether site manufacturing the to have inspection the have interactions a with you regard progress be Congratulations questions. June? sense on thanks Do all taking required? a the following any had in With you FDA submission

Raj Kannan

FDA the Thanks Obviously, Kumar. that we interactions Hi question. with that comment there on. Yes. for ongoing specifically don't is

any are with primary That's is case fourth the not always to case. to we of had recent do always right in in an and regard best remember But remaining time. the to that we why API gun inspection this history not continue the that to inspections, at point before that we reserves our however, and be the inspection out However, given now. be this say supplier, in necessary is going the there launch right taking scheduled we caveat we conduct mentioned FDA jumping guidance the given quarter the still to our that saying that believe and the and conservative putting by

Kumar Raja

with to factor XX-week what trial? with due label two regard extension, time complete what who point and the did the they And not which discontinued clarity regard they to to complete open could the not patients the any are

Raj Kannan

you take Bill, to want it?

Bill Ludlam

Yes.

We haven't have given we the press script any released than what other release further in and today. clarification the

a We overview very the will complete of giving be data.

We with pleased it are academic soon. will very it, and publish setting we upcoming in

clinicians haven't nice into been was maintenance gotten, the XX% got on in. went not we positive, very very, We seeing, a that. further very any with that have and any very further on completed this granularity that details. good We experience at with have and OLE patients point, treatment, thought consistent

Raj Kannan

also the saw would of safety what is were I term. over efficacy And that durability pleased I very Yes. that we longer the say, with and we Kumar, think

period. longer maintained validates much only the a this is So over response

that and hope point So be an data real that able in to clinicians that also for replicated is of important will we adopt And world. the prescribe MYCAPSSA. to be

Kumar Raja

to Ad finally the with the specialty to question one housekeeping supply pharmacy. regard

you revenues supplement in that will the recognizing manufacturing supply quarter the pharmacy. be once to I said before the approval specialty think get last you you If you QX,

So believe? you recognizing revenues those in through if will I comes approval in QX, the QX,

Raj Kannan

ahead. go Mark, Sorry.

Mark Fitzpatrick

Sorry to interrupt you, Raj.

there the So is for Kumar, QX, if recognition company. pharmacy specialty shipment that's revenue in the to event

Kumar Raja

Thanks. Great. Okay.

Operator

This concludes the back closing the turn conference the would remarks. Kannan session. like to over question-and-answer I to for Raj

Raj Kannan

soon. Thanks on we Talk our you continued day wonderful and continued a us always joining look for forward our the today. again. you progress and rest appreciate safe a call Thank Have sharing periodically. update progress of the support all your to We summer. and

Operator

call. conference today's concludes This

your for have participating disconnect Thank you lines. pleasant a may and You day.

Chiasma (CHMA) 10 Aug 202020 Q2 Earnings call transcript